Kyowa Kirin has received FDA approval for an updated dosing regimen of Crysvita, a treatment for X-linked hypophosphatemia (XLH). The new guidelines allow healthcare providers to increase the dose and frequency for patients with low serum phosphorus levels. Crysvita, a monoclonal antibody, targets FGF23 to improve phosphorus retention and vitamin D levels. This update aims to provide a more personalized treatment approach for XLH patients, enhancing their care options.
A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.